Tecavir Dosage/Direction for Use

Compensated liver disease: Recommended dose of Entecavir monohydrate for infection chronic hepatitis B virus in adults and adolescents aged 16 years and over who have not received nucleoside analogue treatment is 0.5 mg once daily with or without food.
Recommended dose of Entecavir monohydrate in adults and adolescents (≥ 16 years) with a history of hepatitis B viremia while receiving lamivudine or lamivudine resistance mutations is known to be 1 mg once daily which should be taken on an empty stomach (at least 2 hours after meals and 2 hours before the next meal).
Decompensated liver disease: The recommended dose of Entecavir monohydrate in adults with decompensated liver disease are 1 mg once daily, which should be taken on an empty stomach (at least 2 hours after eating and 2 hours before the next meal).
Kidney disorders: In patients with renal impairment, Entecavir monohydrate clearance is decreased when it is creatinine clearance decreased. Dosage adjustments are recommended for patients with creatinine clearance <50 mL/minute, including patients on hemodialysis or Continuous Ambulatory Peritoneal Dialysis (CAPD), such as those shown in the table as follows: See Table 1.


Click on icon to see table/diagram/image


* if given on the day of hemodialysis, give Entecavir monohydrate after the hemodialysis session.
Liver Disorders: No dosage adjustment is required for patients with liver disorders.
Duration of Therapy: Optimal duration of treatment with Entecavir monohydrate for patients with viral hepatitis infection B chronic and the relationship between treatment and long-term outcomes such as cirrhosis and carcinoma hepatocellular unknown.